Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Better quality and duration of survival with sunitinib in mRCC

    This is a preview of subscription content, log in to check access.

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Better quality and duration of survival with sunitinib in mRCC. Pharmacoecon. Outcomes News 655, 10 (2012). https://doi.org/10.2165/00151234-201206550-00033

    Download citation

    Keywords

    • Interferon
    • Renal Cell Carcinoma
    • Survival Time
    • British Journal
    • Sunitinib